TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
11.80
-0.45 (-3.67%)
Mar 4, 2026, 12:29 PM CST

Revenue by Segment

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15
New Drug Development and Drug Sales
149.15M119.15M36.23M1.29B23.42M
New Drug Development and Drug Sales Growth
25.18%228.87%-97.20%5426.95%31.74%
Pharmaceutical Technology Consultancy
1.50M3.99M---
Pharmaceutical Technology Consultancy Growth
-62.34%----
Total
150.65M123.13M36.23M1.29B23.42M
Total Growth
22.35%239.87%-97.20%5426.95%15.30%

Revenue by Geography

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15
Taiwan
38.78M30.57M21.03M8.14M6.15M
Taiwan Growth
26.84%45.36%158.45%32.31%-29.95%
Mainland China
111.88M92.57M-1.24B13.72M
Mainland China Growth
20.86%--8953.58%18.94%
Russia
--15.20M-3.46M
South Korea
---44.23M-
Others
----92.00K
Total
150.65M123.13M36.23M1.29B23.42M
Total Growth
22.35%239.87%-97.20%5426.95%15.30%
Source: S&P Global Market Intelligence.